Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xanthofen
- Development stage
- Unknown
- Lead developer
- InQpharm
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IQP-CL-101 (Xanthofen) is a botanical-based therapeutic developed by InQpharm for the symptomatic management of Irritable Bowel Syndrome (IBS). Formulated as a softgel, it is designed to alleviate abdominal pain, bloating, and overall symptom severity in patients suffering from various types of IBS (IBS-C, IBS-D, or IBS-M). Clinical evidence from a double-blind, randomized, placebo-controlled trial (NCT01774825) demonstrated that IQP-CL-101 significantly reduces the IBS Symptom Severity Score (IBS-SSS) compared to placebo over an 8-week period, with significant improvements observed as early as 4 weeks. The product is generally categorized as a herbal medicine or nutraceutical and is intended to improve the quality of life for patients with functional bowel disorders.
- Brand names
- Xanthofen
Beyond the preview
Go deeper on Xanthofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xanthofen.